CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 412 enrolled
Drug / intervention
Aliskiren/Amlodipine +1 moredrug
Likely dose
Aliskiren/Amlodipine 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00942994
NCT00942994Phase 4Completed
CompareCT.gov

An 8-week Multicenter, Randomized, Double-blind, Active Controlled, Parallel Group, Forced Titration Study to Evaluate the Efficacy and Safety of Aliskiren/Amlodipine/HCTZ Compared to Aliskiren/Amlodipine in US Minority Patients With Stage 2 Hypertension

Novartis·interventional·Posted Jul 21, 2009·Updated Jun 8, 2011

In Brief

A Phase 4 clinical trial evaluating Aliskiren/Amlodipine and Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ) for Hypertension. Completed, enrolled 412 participants across 5 sites.

Detailed Summary

The purpose of the study is to compare the combination of aliskiren, amlodipine and Hydrochlorothiazide (HCTZ) versus the combination of aliskiren and amlodipine as therapy in minority Stage 2 hypertensive patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 21, 2009
Enrollment StartJun 1, 2009
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.9 years ago

Interventions

Aliskiren/Amlodipinedrug

Amlodipine capsule (5 mg) Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)

Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)drug

Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg) HCTZ capsule (12.5 mg, 25mg)